Fatty Liver Clinical Trials

160 recruitingLast updated: June 18, 2026

There are 160 actively recruiting fatty liver clinical trials across 37 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 4, Phase 3, Early Phase 1. Top locations include Beijing, Beijing Municipality, China, New York, New York, United States, San Antonio, Texas, United States. Updated daily from ClinicalTrials.gov.


Fatty Liver Trials at a Glance

160 actively recruiting trials for fatty liver are listed on ClinicalTrialsFinder across 6 cities in 37 countries. The largest study group is Not Applicable with 54 trials, with the heaviest enrollment activity in Beijing, New York, and San Antonio. Lead sponsors running fatty liver studies include Cairo University, GlaxoSmithKline, and Tanta University.

Browse fatty liver trials by phase

Treatments under study

About Fatty Liver Clinical Trials

Looking for clinical trials for Fatty Liver? There are currently 18 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Fatty Liver trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Fatty Liver clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 160 trials

Recruiting
Not Applicable

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients

Liver FibrosisNon-alcoholic Fatty Liver Disease NAFLDAlcoholic Liver Disease (ALD)
University Hospital, Angers1,788 enrolled13 locationsNCT05699018
Recruiting
Not Applicable

Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease

MASLDFatty Liver
Henry Ford Health System125 enrolled1 locationNCT07646197
Recruiting

Increased Risk of Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals

Non-Alcoholic Fatty Liver DiseaseLow Birth Weight
Steno Diabetes Center Copenhagen300 enrolled1 locationNCT05890365
Recruiting
Phase 1

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline32 enrolled3 locationsNCT07358546
Recruiting

Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease
Queen Mary University of London153 enrolled1 locationNCT04141592
Recruiting

Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease

FibrosisNonalcoholic SteatohepatitisNonalcoholic Fatty Liver Disease+1 more
Peking Union Medical College Hospital2,000 enrolled1 locationNCT05330923
Recruiting

Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD

Type 2 Diabetes Mellitus (T2DM)MASH - Metabolic Dysfunction-Associated SteatohepatitisMetabolic Dysfunction-associated Fatty Liver Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School10,000 enrolled22 locationsNCT07632677
Recruiting

A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes

NAFLD - Non-Alcoholic Fatty Liver DiseaseNAFLD and NASHNAFLD Cirrhosis
The Affiliated Hospital of Hangzhou Normal University20,000 enrolled1 locationNCT07241195
Recruiting
Not Applicable

The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults

OverweightFatty Liver Disease
TCI Co., Ltd.124 enrolled1 locationNCT04496895
Recruiting
Phase 2

Digoxin In NASH (CODIN)

MASLDMASH - Metabolic Dysfunction-Associated SteatohepatitisFatty Liver Disease+5 more
Yale University144 enrolled2 locationsNCT06588699
Recruiting

Identification of Liver Fibrosis Biomarkers

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic SteatohepatitisNon-alcoholic Fatty Liver
Roche Diagnostics GmbH575 enrolled2 locationsNCT06819917
Recruiting
Phase 1

Evaluating the Pharmacokinetics and Safety of Miricorilant

Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663
Recruiting
Not Applicable

Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues

Non-Alcoholic Fatty Liver DiseaseSubclinical hypothyroïdismPrimary Open Angle Glaucoma
Cairo University40 enrolled1 locationNCT07599241
Recruiting

Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population

Fatty Liver
Methodist Health System300 enrolled1 locationNCT06225193
Recruiting

Early Tracking of Childhood Health Determinants (ETCHED) Study

Diabetes MellitusObesityFatty Liver
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1,500 enrolled1 locationNCT03481829
Recruiting
Phase 2

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)84 enrolled1 locationNCT03884075
Recruiting
Phase 2

Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

Non-Alcoholic Fatty Liver Disease
Tanta University46 enrolled1 locationNCT06863376
Recruiting
Phase 2

Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial

MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseFatty Liver Disease, NonalcoholicOverweight (BMI > 25)
AB Biotics, SA60 enrolled1 locationNCT07193927
Recruiting

Liver Steatosis in Pediatric CD Patients

Non-Alcoholic Fatty Liver DiseaseCeliac Disease in Children
University of Palermo91 enrolled2 locationsNCT06206616
Recruiting

Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease

Liver NeoplasmLiver FibrosisHBV Infection+1 more
Nanfang Hospital, Southern Medical University240 enrolled1 locationNCT07265544